Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae
Launched by THE UNIVERSITY OF HONG KONG · Jul 31, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a treatment called fecal microbiota transplantation (FMT) to help patients who have an infection from a type of bacteria known as carbapenem-resistant Enterobacteriaceae (CRE). CRE infections are a serious concern in healthcare, especially in Hong Kong, where cases have significantly increased in recent years. The idea behind this trial is that by transferring healthy stool from a donor into a patient's intestines, we might be able to restore a healthy balance of gut bacteria. This could potentially help clear the CRE infection.
To participate in the trial, you need to be an adult aged 18 or older and currently admitted to the medical ward of Queen Mary Hospital. You must also have tested positive for CRE within the last week. However, this trial is not for everyone. People who are pregnant, have certain severe health conditions, or have taken antibiotics recently may not be eligible. If you join the trial, you will receive treatment through an enema, which is a way to deliver the donor stool directly into your intestines. This trial is still in the planning stage and has not started recruiting participants yet.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All adult patients aged 18 or above admitted to the medical ward of Queen Mary Hospital, the teaching hospital of the University of Hong Kong
- • Rectal swabs or stool specimens showing the presence of CRE
- • Positive CRE specimen within one week of commencement
- Exclusion Criteria:
- • Pregnancy
- • Severe immunodeficiency (e.g. advanced human immunodeficiency virus infection (CD4 lymphocyte count ≤200/mm3), myelosuppressive chemotherapy)
- • Significant neutropenia (absolute neutrophil count ≤1.0 x 109/L)
- • Recent antibiotic use within 30 days prior to consent
- • Contraindications for retention enema (intestinal obstruction, ileus and gut perforation).
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Ka Shing Cheung
Principal Investigator
The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported